Navigation Links
Roundtable of Biopharma Industry Leaders Offers Insights to Market Access Challenges

NEW YORK, Dec. 2, 2013 /PRNewswire/ -- Promidian, an Access Group company, recently participated in a feature roundtable hosted by Pharmaceutical Executive to discuss how market access dynamics are likely to evolve over the next few years and the implications of this evolution for biopharma companies. A recap of the highlights of the panel discussion is featured in the November issue of the magazine and is available upon request through Promidian at

The roundtable participants, including executives from the biopharma industry, consulting firms, and trade organizations, brought to the forefront the emerging issues related to market access. This market access dilemma has significant strategic and operational implications for the way the industry develops, launches, and promotes drugs.

"This was a unique forum that brought together a diverse group of industry stakeholders to focus on the issue of where market access is going and what this means for biopharma companies," said Kevin Barnett, Executive Vice President and Managing Director at Promidian.

The roundtable discussions covered a wide range of topics, including how market access dynamics are expected to evolve over the next few years, therapeutic areas that are expected to be among the highest priorities with payers, changes in payment and care delivery models, what payers want from drug manufacturers, and requirements for market access success for biopharma companies vis-a-vis the evolving marketplace.

New Research by Promidian Drives Discussions at Pharmaceutical Executive Roundtable
The dynamic dialogue during the roundtable was fueled by a review of findings from Promidian's Future of Market Access study. The study involved both primary research with managed market executives and market access key opinion leaders (including those from managed care organizations, pharmacy benefit managers, Medicaid, employers, and accountable care organizations) and primary research with executives from leading biopharma companies. Key areas of focus in the study include

  • Where the most change is expected in managed care and market access
  • The degree to which and how the Affordable Care Act will affect business
  • Top business priorities for managed care
  • Therapeutic categories that represent the highest priorities for payers
  • The biggest market access-related challenges and priorities for biopharma
  • Expectations on what will happen with biosimilars and comparative effectiveness research
  • Which biopharma companies are most effective in dealing with payers, and what differentiates these companies
  • Opportunities and requirements for biopharma companies to positively differentiate themselves in the way they interact and conduct business with payers
  • Assessment of how perceptions and expectations of payers and manufacturers compare across the questions included in the study

"Based on our research, market access dynamics are expected to change dramatically over the next three to five years in a number of areas, ranging from the role of biomarkers, information technology, and comparative effectiveness standards to benefit and formulary design and contracting," said Barnett. "Biopharma companies need to understand and address the implications of these changes to be successful in the forthcoming environment. Our research with payers identified those biopharma companies that are perceived to be best positioned for success over the next few years," he added.

About Promidian
Promidian, an Access Group company, is a management consulting firm that is focused on the pharmaceutical, biotechnology, and life sciences industries. We combine deep industry and functional area knowledge with specialized expertise in market assessment and strategy development—to assist life sciences executives in addressing their most pressing business challenges. For more information, visit You may also contact Kevin Barnett at

About the Access Group
The Access Group is the leading independent strategic health care communications network composed of 8 distinct companies: Access Alliance, Access Communications, Catalyst, Fusion Medical Communications, MedAccess, Promidian, S3—Strategic Selling Solutions, and StrataMed. The firm is headquartered in Berkeley Heights, New Jersey, with offices in New York City, Chicago, San Francisco, and San Diego. 

SOURCE Promidian
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Legislation To Make USPSTF More Transparent: Prostate Cancer Roundtable Supports Reform
2. RoundTable Healthcare Partners Portfolio Company, Renaissance Acquisition Holdings, LLC Acquires DPT Laboratories
3. RoundTable Healthcare Partners Announces Sale of Aspen Surgical Products Holding, Inc. to Hill-Rom Holdings, Inc.
4. RoundTable Healthcare Partners and Argon Medical Devices to Acquire Angiotech Pharmaceuticals Interventional Products Business
5. Contract Manufacturer RMI hosts Central Indiana Jobs Roundtable with U.S. Senator Joe Donnelly
6. RoundTable Healthcare Partners and Argon Medical Devices Complete Acquisition of Angiotech Pharmaceuticals Interventional Products Business
7. Isis Pharmaceuticals to Present at the Leerink Swann Rare Disease Roundtable
8. Patient Recruitment Expert CSS Tapped to Host Master Workshop and Roundtable Discussions at Annual SCRS Site Solutions Summit Conference in October
9. Mast Therapeutics To Present At The Leerink Swann Rare Disease Roundtable On October 2
10. KaloBios to Present at Leerink Swann Rare Disease Roundtable
11. 2013 mHealth Summit Launches First Pharma and Life Sciences Roundtable
Post Your Comments:
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):